Hologic has closed its previously announced acquisition of surgical instrument manufacturer Bolder Surgical.
The acquisition adds Bolder Surgical’s advanced vessel sealing, dividing and dissection tools for laparoscopic procedures to Hologic’s surgical portfolio. It will also enable Hologic to offer Bolder’s devices to obstetrician-gynaecologist (OB/GYN) specialists.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bolder Surgical offered its products across all 50 US states, as well as the international market.
As part of the agreement, all Bolder devices, such as the CoolSeal Vessel Sealing Suite, JustRight 3mm vessel sealer and JustRight 5mm stapler, will be moved to the Hologic Surgical portfolio immediately.
Hologic surgical division president Essex Mitchell said: “The acquisition of Bolder Surgical will expand Hologic’s growing laparoscopic portfolio and underscores our commitment to women’s health.
“We will better serve our existing physician base with Bolder’s minimally invasive treatments and advanced vessel sealing technology.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn October, Hologic signed a definitive agreement to acquire Bolder Surgical for nearly $160m. Bolder Surgical will deliver around $10m of product revenue this calendar year.
At the time of the announcement, Bolder Surgical president and CEO Robert Kline said: “Becoming part of Hologic and its highly respected and well-known surgical business is an exciting and pivotal junction for Bolder.
“Together, we will accelerate realising Bolder’s vision to increase the efficiency of both surgeons and hospitals. Joining Hologic, with its similar mission, culture and world-class portfolio of products, is an ideal fit for Bolder.”
Headquartered in Massachusetts, US, Hologic is a women’s health-focused medical technology company.
In the fourth quarter of the fiscal year (FY21), which ended on 25 September, the company recorded a 2.3% year on year (YoY) fall in revenue to $1.32bn, due to lower Covid-19 assay sales.
